

In vitro models of fibrotic cardiac tissue as a potential tool for testing cardioprotective therapies for cardiovascular diseases related to COVID-19

Original

In vitro models of fibrotic cardiac tissue as a potential tool for testing cardioprotective therapies for cardiovascular diseases related to COVID-19 / Spedicati, Mattia; Ruocco, Gerardina; Zoso, Alice; Carmagnola, Irene; Chiono, Valeria. - ELETTRONICO. - (2020). (Virtual FISV Symposium on SARS-CoV-2 Biology and COVID-19: Current research and perspectives).

Availability:

This version is available at: 11583/2872048 since: 2021-02-19T17:06:57Z

Publisher:

FISV - Federazione Italiana Scienze della Vita

Published

DOI:

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

In vitro models of fibrotic cardiac tissue as a potential tools for testing cardioprotective therapies for cardiovascular diseases related to COVID-19

Mattia Spedicati^{1,2,3}, Gerardina Ruocco^{1,2,3}, Alice Zoso^{1,2,3}, Irene Carmagnola^{1,2,3}, Valeria Chiono^{1,2,3}

¹ Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy;

² POLITO Biomedlab, Politecnico di Torino, Turin, Italy;

³ Interuniversity Center for the promotion of the 3Rs principles in teaching and research, Italy.

COVID-19 may causes cardiac fibrosis and decompensation. Hence, effective therapies are needed to recover heart functionality after SARS-CoV-2 infection. *In vitro* models of pathological cardiac tissue could be predictable platforms for preclinical trials.

In this work, ventricular human cardiac fibroblasts (HCFs) were cultured on biomimetic scaffolds to reproduce different sizes of pathological cardiac tissue. 2D and 3D polycaprolactone (PCL) scaffolds, respectively made by electrospinning and fused deposition modelling, were grafted with gelatin to confer biomimetic properties. Gelatin coating favored cell attachment and proliferation and supported their extracellular matrix deposition (“biomatrix”) within 21 days culture time. Scaffold architecture affected the expression of fibroblast markers (α -SMA) and biomatrix features. The obtained *in vitro* models of cardiac fibrotic tissue could be exploited as testing platform for drugs (e.g. reprogramming microRNAs) aimed at reducing adverse effects on heart due to SARS-CoV-2.

This research was supported by BIORECAR project funded from European Research Council (ERC) under EU’s Horizon 2020 programme (grant agreement No 772168).

References

1. Zachary D Demertzis, Carina Dagher, Kelly M Malette, Raef A Fadel, Patrick B Bradley, Indira Brar, Bobak T Rabbani, Geehan Suleyman, Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series, European Heart Journal - Case Reports